Prognostic Value of Pulmonary Artery Pulsatility Index in Right Ventricle Failure-Related Mortality in Inoperable Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is an ominous disease leading to progressive right ventricular failure (RVF) and death. There is no reliable risk stratification strategy for patients with CTEPH. The pulmonary artery pulsatility index (PAPI) is a novel hemodynamic index that predicts the occurrence RVF. We aimed to investigate prognostic value of PAPI in inoperable CTEPH. Consecutive patients with inoperable CTEPH were enrolled. PAPI was calculated from baseline right heart catheterization data. A prognostic cut-off value was determined, and characteristics of low- and high-PAPI groups were compared. The association between risk assessment and survival was also evaluated. We included 50 patients (mean age 64 ± 12.2 years, 60% female). The number of deaths was 12 (24%), and the mean follow-up time was 52 ± 19.3 months. The established prognostic cut-off value for PAPI was 3.9. The low-PAPI group had significantly higher mean values of mean atrial pressure (14.9 vs. 7.8, p = 0.0001), end-diastolic right ventricular pressure (16.5 vs. 11.2, p = 0.004), and diastolic pulmonary artery pressure (35.8 vs. 27.7, p = 0.0012). The low-PAPI group had lower survival as compared to high-PAPI (log-rank p < 0.0001). PAPI was independently associated with survival and may be applicable for risk stratification in inoperable CTEPH.

[1]  M. Lesiak,et al.  Association of Electrocardiographic Signs of Right Ventricular Hypertrophy and Clot Localization in Chronic Thromboembolic Pulmonary Hypertension , 2022, Journal of clinical medicine.

[2]  M. Cova,et al.  Chronic Thromboembolic Pulmonary Hypertension: An Update , 2022, Diagnostics.

[3]  A. Torbicki,et al.  Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Registry. , 2021, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  E. Tay,et al.  Does pulmonary artery pulsatility index predict mortality in pulmonary arterial hypertension? , 2021, ESC heart failure.

[5]  J. Hossack,et al.  Pulmonary Artery Proportional Pulse Pressure (PAPP) Index Identifies Patients With Improved Survival From the CardioMEMS Implantable Pulmonary Artery Pressure Monitor. , 2021, Heart, lung & circulation.

[6]  A. Torbicki,et al.  Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL) , 2021, Therapeutic advances in chronic disease.

[7]  A. Torbicki,et al.  Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension , 2021, Journal of clinical medicine.

[8]  D. Schranz,et al.  Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertension-a registry-based analysis. , 2021, Cardiovascular diagnosis and therapy.

[9]  M. Hutyra,et al.  Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile , 2020, Journal of clinical medicine.

[10]  S. Söderberg,et al.  Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival , 2020, Scandinavian cardiovascular journal : SCJ.

[11]  A. Torbicki,et al.  Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team , 2019, Therapeutic advances in respiratory disease.

[12]  K. Fukuda,et al.  Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hypertension: A Japanese Perspective. , 2019, JACC. Cardiovascular interventions.

[13]  A. Torbicki,et al.  Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. , 2019, International journal of cardiology.

[14]  E. Novak,et al.  The Combination of Tricuspid Annular Plane Systolic Excursion and HeartMate Risk Score Predicts Right Ventricular Failure After Left Ventricular Assist Device Implantation , 2019, ASAIO journal.

[15]  E. Tay,et al.  Pulmonary arterial hypertension in a multi‐ethnic Asian population: Characteristics, survival and mortality predictors from a 14‐year follow‐up study , 2018, Respirology.

[16]  S. Rosenkranz,et al.  Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients , 2018, European Respiratory Journal.

[17]  V. Topkara,et al.  Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial. , 2018, Journal of cardiac failure.

[18]  A. Naito,et al.  Long-Term Outcome of Chronic Thromboembolic Pulmonary Hypertension at a Single Japanese Pulmonary Endarterectomy Center. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[19]  H. Ghofrani,et al.  Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.

[20]  N. Kapur,et al.  Pulmonary Artery Pulsatility Index Is Associated With Right Ventricular Failure After Left Ventricular Assist Device Surgery. , 2016, Journal of cardiac failure.

[21]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[22]  D. Banerjee,et al.  Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  A. Torbicki,et al.  Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. Joint statement of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions. , 2015, Kardiologia polska.

[24]  H. Ghofrani,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) , 2014, European Respiratory Journal.

[25]  Chen Wang,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.

[26]  Yuhui Zhang,et al.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. , 2013, Chest.

[27]  A. Ogawa,et al.  Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension , 2012, Circulation. Cardiovascular interventions.

[28]  James O. Mudd,et al.  The pulmonary artery pulsatility index identifies severe right ventricular dysfunction in acute inferior myocardial infarction , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[29]  R. Naeije,et al.  The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease , 2012, European Respiratory Journal.

[30]  J. Barberà,et al.  Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry , 2011, Circulation.

[31]  N. Westerhof,et al.  Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. , 2009, Respiratory medicine.

[32]  P. Thistlethwaite,et al.  Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. , 2002, The Journal of thoracic and cardiovascular surgery.

[33]  G. V. Kass An Exploratory Technique for Investigating Large Quantities of Categorical Data , 1980 .